According to MorphoSys, the deal will allow it to improve the success rate for new antibody drug candidate development to the point where 50 percent of new projects will reach clinical development.
The new venture also will work with Novartis on accelerating the production of influenza seed strains required for vaccine manufacturing.
The firm is developing synthetic promoters, regulatory DNA sequences created by picking out the regulatory regions in a gene, "chopping them up," and then putting them back together.
In October, Origene also purchased Marligen Biosciences, and in recent months it has forged partnerships with multiple companies, expanding its foot print in the life sciences.
The software, called GenoTHREAT, is intended to help gene synthesis companies and their customers detect the possible use of manufactured DNA as a bioterrorism agent.
In Brief This Week is a Friday column containing news items that our readers may have missed during the week.
The bioterrorism and WMD law would begin to create a safety network of rules for labs handling top-tier pathogens or chemicals, and would also take tackle synthetic genomics.
With two recent deals, Life Tech hopes to capitalize on the synthetic biology market, which is projected to grow to $2.4 billion by 2013.
Synthetic Genomics funded the work by Craig Venter that resulted in the first functional bacterial cells controlled by a synthetic genome.
Life Tech now owns 74 percent of the synthetic gene company.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.